CDKN2A and neoplasm: Comprehensive genomic analysis of HNCHPV+ tumor data, obtained from the Cancer Genome Atlas (TCGA), showed a low frequency of genomic alteration in TP53 (p53; 3%) and no mutations in CDKN2A (p16), when compared to HNCHPV−, in which 84% of the cases exhibit mutations in p53 and 57% cases exhibit mutations in p16, respectively [18].